About: International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) ലേഖനം (ml) հոդված (hy) wetenschappelijk artikel (nl) article scientifique publié en 2009 (fr) наукова стаття, опублікована в січні 2010 (uk) im November 2009 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q56447686-89799B1E-36EF-4CFF-97EF-0D70E968B219
publication date	2009-11-17 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56447686-0EF2305A-DA34-4F60-9863-330DE2FB38D2
language of work or name	English
cites work	wds:Q56447686-080030F6-0F92-4DE3-87C7-0A53AF4E3540 wds:Q56447686-1919BBC6-717E-4367-AA46-3F7AA571EDF4 wds:Q56447686-1D1B9230-4A24-4648-B8E9-6620B904B174 wds:Q56447686-21401F3C-D173-4F0A-AEAD-D981051ABF8C wds:Q56447686-2E356358-0A71-4C1F-8D7B-44B7D8E71714 wds:Q56447686-3D45AF60-5024-496A-A3E3-721598386FAE wds:Q56447686-3D74A1A4-456A-4E6C-A1ED-27EDDF2D1462 wds:Q56447686-40E8BAB3-3A78-4F2A-9B35-FB683C3C84DA wds:Q56447686-467C3620-9B3F-4B48-B5B2-96BFA873B3A5 wds:Q56447686-49D677BA-253A-4456-B573-F295F53A056D wds:Q56447686-4A7560B0-CED3-49FC-8D88-AACB1D33F293 wds:Q56447686-55E35CE5-4EEB-44C0-B859-24FFA735894F wds:Q56447686-689BE691-B7F8-4B7A-9EAD-C3E64D63CCB5 wds:Q56447686-76E6924A-411F-4C15-A0EB-402C26AA689A wds:Q56447686-83FE4E70-26E9-4CA9-A3B2-E5EDA4F6393E wds:Q56447686-88BB2404-5748-428C-AD03-8548DA443769 wds:Q56447686-8A8E1EAC-CC8D-4DCD-BACC-C0A9E19CC4AC wds:Q56447686-988D44AE-CBB5-4A5C-B825-68684448B4A7 wds:Q56447686-99A73AD6-90FA-4443-81DA-8905E7634D15 wds:Q56447686-9C71E049-E96A-4B50-9107-8D0E7AD8B188 wds:Q56447686-9E572195-EDD9-4C2E-B681-728ED3B4A2A0 wds:Q56447686-ABBA3577-52AA-4AA6-97D5-E20026072094 wds:Q56447686-AD38BC4D-E598-437F-ABF4-C3BE96E74F5A wds:Q56447686-AE31BECB-3C32-4DB1-AE53-11D06A1E7F7E wds:Q56447686-B1E4063C-EE6A-4F25-9472-6489ACA5F7C1 wds:Q56447686-D20C5C55-7BBB-4402-A466-CB3ABAAED23A wds:Q56447686-D90FF42A-FF37-4596-B78C-922FFD68DDEA wds:Q56447686-D9A25731-0942-4406-85F1-1C867206EAB1 wds:Q56447686-DE2B2638-0DEE-4CED-BFB8-8BFCAB11BA08 wds:Q56447686-E05865EF-CBDC-4FEF-B140-3842D48E09EA wds:Q56447686-E6BEBA92-3F91-4119-9F1E-B12CBA7B7647 wds:Q56447686-EDC3215F-A569-404F-AB0B-60AEC28DC0E8 wds:Q56447686-F3B9C64F-4A55-4DF9-AC30-A5990DEDD535 wds:Q56447686-F82953E7-793B-47CE-AB77-475803ED3F2F
cites work	Adenoviruses as vaccine vectors Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector Immune responses to adenovirus and adeno-associated virus in humans. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis Overcoming immunity to a viral vaccine by DNA priming before vector boosting Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene Viral vectors in malaria vaccine development Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D Age-related decrease in adenovirus-specific T cell responses. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines Neutralizing antibodies against 33 human adenoviruses in normal children in Rome HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa
author name string	wds:Q56447686-1A64861E-D68F-4A84-A2C2-D8D1A810C161 wds:Q56447686-452081D1-FE6A-4D1B-847B-718DFF2D3360 wds:Q56447686-48FE7F71-EB17-47EC-A50F-FE2D758CA7AD wds:Q56447686-AD47B4D8-88DE-498D-84C0-C1AE54780CDC wds:Q56447686-B3864DB1-68F5-4F19-9E1B-E7CA8BA2402C wds:Q56447686-B3D22ACF-41BE-471C-A4AF-4E896D90D9D2 wds:Q56447686-BCB32B9E-4AC5-45A4-B9AB-FFB811210F52 wds:Q56447686-C85CC9D4-E722-421D-98C3-E3557F2BC482 wds:Q56447686-DD381CC9-4356-471E-B796-2EC411FC324B wds:Q56447686-EBE1A3B6-721F-472F-B733-30A5B586409D wds:Q56447686-EE2BC7E5-28C2-4C28-88DE-69F717D6CC54 wds:Q56447686-F11DC858-A048-47BE-8D27-05003B9A31AE
author name string	Mauro Schechter John W Shiver Danilo R Casimiro Bernard Mbewe Vladimir Novitsky T Christopher Mast Swati B Gupta Walter L Straus

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software